Status:
COMPLETED
Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
Lead Sponsor:
Gilead Sciences
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
Detailed Description
Subjects in these randomized studies will receive one of two doses of ambrisentan or placebo. Inclusion is not based on a specified WHO functional classification. Rather, subjects with WHO Class I-IV ...
Eligibility Criteria
Inclusion
- 18 years of age or order
- Current diagnosis of either PPH orPAH secondary to the scleroderma spectrum of disease, systemic lupus erythematosus, anorexigen use, or HIV infection at the Screening Visit
- Right heart catheterization, completed prior to Screening Visit must meet pre-specified hemodynamic criteria
- Female subjects of childbearing potential must have a negative serum pregnancy test and must agree to use a reliable double barrier method of contraception until study completion and for at least four weeks following their final study visit
- Male subjects must be informed of the potential risks of testicular tubular atrophy and infertility associated with taking this study drug and queried regarding his understanding of the potential risks as described in the Informed Consent Form
Exclusion
- PAH due to or associated with congenital heart disease, coronary artery disease, left heart disease, interstitial lung disease, chronic obstructive pulmonary disease, veno-occlusive disease, chronic thrombotic and/or embolic disease, or sleep apnea
- Portopulmonary hypertension
- Bosentan within four weeks prior to Screening
- Phosphodiesterase type V inhibitor or chronic prostanoid therapy within four weeks prior to Screening
- IV inotrope use within two weeks prior to Screening
- ALT or AST lab value that is greater than 1.5 times the upper limit of normal
- Pulmonary function tests not meeting pre-specified criteria
- Contraindication to treatment with an ERA
- History of malignancies other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the past five years
- Females who are pregnant or breastfeeding
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT00423748
Start Date
December 1 2003
End Date
February 1 2006
Last Update
April 16 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.